A landmark multi-country study published in The Lancet has confirmed the significant impact of deploying Truenat molecular diagnostics at the primary care level. Conducted across clinics in Tanzania and Mozambique, the study showed that 82.2% of TB patients tested with Truenat were able to begin treatment on the same day—compared to just 3% in clinics using off-site GeneXpert testing. Mortality was also three times lower in the Truenat group. The research underscores that battery-operated, WHO-endorsed platforms like Truenat can close diagnostic gaps, replace outdated microscopy, and enable true point-of-care testing in low-resource settings—making timely TB diagnosis and treatment a practical reality.